Avidity Biosciences Inc (RNA)
26.58
+1.00
(+3.91%)
USD |
NASDAQ |
May 03, 14:07
Avidity Biosciences Research and Development Expense (Quarterly): 52.82M for Dec. 31, 2023
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 52.82M |
| September 30, 2023 | 47.71M |
| June 30, 2023 | 42.67M |
| March 31, 2023 | 47.76M |
| December 31, 2022 | 45.61M |
| September 30, 2022 | 37.32M |
| June 30, 2022 | 39.79M |
| March 31, 2022 | 27.69M |
| December 31, 2021 | 32.97M |
| September 30, 2021 | 24.83M |
| Date | Value |
|---|---|
| June 30, 2021 | 22.71M |
| March 31, 2021 | 20.68M |
| December 31, 2020 | 13.62M |
| September 30, 2020 | 9.455M |
| June 30, 2020 | 8.984M |
| March 31, 2020 | 5.544M |
| December 31, 2019 | 5.645M |
| September 30, 2019 | 5.099M |
| June 30, 2019 | 2.533M |
| March 31, 2019 | 1.262M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.533M
Minimum
Jun 2019
52.82M
Maximum
Dec 2023
25.97M
Average
24.83M
Median
Sep 2021
Research and Development Expense (Quarterly) Benchmarks
| Ironwood Pharmaceuticals Inc | 35.68M |
| Codexis Inc | 11.23M |
| HOOKIPA Pharma Inc | 21.16M |
| DocGo Inc | 3.186M |
| Kineta Inc | 1.561M |